Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects

NeuroImage

Volumn 40, Issue 3, 2008, Pages 1222-1231

  Vernaleken, Ingo ^a   Kumakura, Yoshitaka ^b   Buchholz, Hans Georg ^c   Siessmeier, Thomas ^c   Hilgers, Ralf Dieter ^a   Bartenstein, Peter ^d   Cumming, Paul ^e   Gründer, Gerhard ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF TOKYO   (Japan)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Neuroscience Research Unit   (Denmark)

Author keywords

18F Fluoro l DOPA; Antipsychotic treatment; Cognition; Dopamine; Striatum

Indexed keywords

6 FLUORODOPA F 18; 6 FLUORODOPAMINE; CARBIDOPA; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUORODOPAMINE F 18; HALOPERIDOL; UNCLASSIFIED DRUG; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ACUTE DRUG ADMINISTRATION; ADULT; ARTICLE; BOLUS INJECTION; COGNITION; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; HUMAN; HUMAN EXPERIMENT; MALE; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STEADY STATE; TASK PERFORMANCE; ALGORITHM; BRAIN; BRAIN LEVEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PREDICTION AND FORECASTING; PSYCHOMOTOR PERFORMANCE; SCINTISCANNING; STATISTICAL ANALYSIS;

ADULT; ALGORITHMS; BRAIN; BRAIN CHEMISTRY; COGNITION; DATA INTERPRETATION, STATISTICAL; DOPAMINE; DOPAMINE ANTAGONISTS; FEMALE; FLUORODEOXYGLUCOSE F18; HALOPERIDOL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PSYCHOMOTOR PERFORMANCE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 40849096177     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2007.12.045     Document Type: Article

References (46)

1. Aaronson D., and Watts B. Extensions of Grier's computational formulas for A' and B'' to below-chance performance. Psychol. Bull. 102 (1987) 439-442
2. Arnsten A.F. Catecholamine regulation of the prefrontal cortex. J. Psychopharmacol. 11 (1997) 151-162
3. Arnsten A.F., Cai J.X., Murphy B.L., and Goldman-Rakic P.S. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 116 (1994) 143-151
4. Bowers Jr. M.B., Swigar M.E., Jatlow P.I., and Goicoechea N. Plasma catecholamine metabolites and early response to haloperidol. J. Clin. Psychiatry 45 (1984) 248-251
5. Castner S.A., Williams G.V., and Goldman-Rakic P.S. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287 (2000) 2020-2022
6. Chuang-Stein C. The regression fallacy. Drug Inf. J. 27 (1993) 1213-1220
7. Cumming P., and Gjedde A. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms. Synapse 29 (1998) 37-61
8. Cumming P., Ase A., Laliberte C., Kuwabara H., and Gjedde A. In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain. J. Cereb. Blood Flow Metab. 17 (1997) 1254-1260
9. Cumming P., Kuwabara H., and Gjedde A. A kinetic analysis of 6-[18F]fluoro-l-dihydroxyphenylalanine metabolism in the rat. J. Neurochem. 63 (1994) 1675-1682
10. Cumming P., Leger G.C., Kuwabara H., and Gjedde A. Pharmacokinetics of plasma 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans. J. Cereb. Blood Flow Metab. 13 (1993) 668-675
11. Danielsen E.H., Smith D., Hermansen F., Gjedde A., and Cumming P. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Synapse 41 (2001) 172-175
12. Davidson M., Giordani A.B., Mohs R.C., Horvath T.B., Davis B.M., Powchik P., and Davis K.L. Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration. Arch. Gen. Psychiatry 44 (1987) 189-190
13. Davila R. Plasma HVA, neuroleptics, and dopaminergic plasticity. Biol. Psychiatry 25 (1989) 1-3
14. Davila R., Manero E., Zumarraga M., Andia I., Schweitzer J.W., and Friedhoff A.J. Plasma homovanillic acid as a predictor of response to neuroleptics. Arch. Gen. Psychiatry 45 (1988) 564-567
15. Dhawan V., Ishikawa T., Patlak C.S., and Eidelberg D. Controversies arising from recent FDOPA articles [Letter]. J. Nucl. Med. 38 (1997) 1270-1271
16. Gillings N.M., Bender D., Falborg L., Marthi K., Munk O.L., and Cumming P. Kinetics of the metabolism of four PET radioligands in living minipigs. Nucl. Med. Biol. 28 (2001) 97-104
17. Gjedde A., Reith J., Dyve S., Leger G., Guttman M., Diksic M., Evans A., and Kuwabara H. Dopa decarboxylase activity of the living human brain. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 2721-2725
18. Granholm E., Verney S., and Nuechterlein K. Degraded Stimulus Continuous Performance Test Deficits in Older Patients with Schizophrenia (2003), Society for Research in Psychopathology Annual Meeting, Toronto, CA
19. Gründer G., Vernaleken I., Muller M.J., Davids E., Heydari N., Buchholz H.G., Bartenstein P., Munk O.L., Stoeter P., Wong D.F., Gjedde A., and Cumming P. Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 28 (2003) 787-794
20. Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6 (1979) 65-70
21. Huang S.C., Yu D.C., Barrio J.R., Grafton S., Melega W.P., Hoffman J.M., Satyamurthy N., Mazziotta J.C., and Phelps M.E. Kinetics and modeling of l-6-[18F]fluoro-dopa in human positron emission tomographic studies. J. Cereb. Blood Flow Metab. 11 (1991) 898-913
22. Kathmann N., Wagner M., Satzger W., and Engel R.R. Vigilanzmessung auf Verhaltensebene: Der Continuous Performance Test-München (CPT-M). In: Moller H.-J., Engel R.R., and Hoff P. (Eds). Befunderhebungin der Psychiatrie: Lebensqualität, Negativsymptomatik und andere aktuelle Entwicklungen (1996), Springer, Wien, Austria 331-338
23. Kumakura Y., Cumming P., Vernaleken I., Buchholz H.G., Siessmeie T., Heinz A., Kienast T., Bartenstein P., and Gründer G. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J. Neurosci. 27 30 (2007) 8080-8087
24. Kumakura Y., Gjedde A., Danielsen E.H., Christensen S., and Cumming P. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms. J. Cereb. Blood Flow Metab. 26 (2006) 358-370
25. Kumakura Y., Vernaleken I., Gründer G., Bartenstein P., Gjedde A., and Cumming P. PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity. J. Cereb. Blood Flow Metab. 25 (2005) 807-819
26. Kumakura Y., Danielsen E.H., Reilhac A., Gjedde A., and Cumming P. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease. Acta Neurol. Scand. 110 (2004) 188-195
27. Legangneux E., McEwen J., Wesnes K.A., Bergougnan L., Miget N., Canal M., L'Heritier C., Pinquier J.L., and Rosenzweig P. The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. J. Psychopharmacol. 14 (2000) 164-171
28. Magliozzi J.R., Doran A.R., Gietzen D.W., Olson A.M., Maclin E.L., and Tuason V.B. Effects of single dose haloperidol administration on plasma homovanillic acid levels in normal subjects. Psychiatry Res. 47 (1993) 141-149
29. Mass R., Wolf K., Wagner M., and Haasen C. Differential sustained attention/vigilance changes over time in schizophrenics and controls during a degraded stimulus Continuous Performance Test. Eur. Arch. Psychiatry Clin. Neurosci. 250 (2000) 24-30
30. McGowan S., Lawrence A.D., Sales T., Quested D., and Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch. Gen. Psychiatry 61 (2004) 134-142
31. Meyer-Lindenberg A., Kohn P.D., Kolachana B., Kippenhan S., McInerney-Leo A., Nussbaum R., Weinberger D.R., and Berman K.F. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat. Neurosci. 8 (2005) 594-596
32. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., and Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 5 (2002) 267-271
33. Morrens M., Wezenberg E., Verkes R.J., Hulstijn W., Ruigt G.S., and Sabbe B.G. Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration. J. Clin. Psychopharmacol. 27 (2007) 15-21
34. Pickar D., Labarca R., Doran A.R., Wolkowitz O.M., Roy A., Breier A., Linnoila M., and Paul S.M. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Arch. Gen. Psychiatry 43 (1986) 669-676
35. Rammsayer T., and Gallhofer B. Remoxipride versus haloperidol in healthy volunteers: psychometric performance and subjective tolerance profiles. Int. Clin. Psychopharmacol. 10 (1995) 31-37
36. Rayevsky K.S., Gainetdinov R.R., Grekhova T.V., and Sotnikova T.D. Regulation of dopamine release and metabolism in rat striatum in vivo: effects of dopamine receptor antagonists. Prog. Neuropsychopharmacol. Biol. Psychiatry 19 (1995) 1285-1303
37. Rosvold H.E., Mirsky A.F., Sarason I., Bransome E.D., and Beck L.H. A continuous performance test of brain damage. J. Consult. Psychol. 20 (1956) 343-350
38. Silverstein S., Light G., and Palumbo D. The sustained attention test: a measure of attentional disturbance. Comput. Hum. Behav. 14 (1998) 463-475
39. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 212 (1970) 11-19
40. Sossi V., Holden J.E., de la Fuente-Fernandez R., Ruth T.J., and Stoessl A.J. Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant Kocc and the [18F]fluorodopa plasma input uptake rate constant Ki. J. Cereb. Blood Flow Metab. 23 (2003) 301-309
41. Vernaleken I., Buchholz H.G., Kumakura Y., Siessmeier T., Stoeter P., Bartenstein P., Cumming P., and Gründer G. 'Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-l-DOPA-PET investigation. Hum. Brain Mapp. 28 10 (2007) 931-939
42. Vernaleken I., Kumakura Y., Cumming P., Buchholz H.G., Siessmeier T., Stoeter P., Muller M.J., Bartenstein P., and Gründer G. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage 30 (2006) 1332-1339
43. Vijayraghavan S., Wang M., Birnbaum S.G., Williams G.V., and Arnsten A.F. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci. 10 (2007) 376-384
44. Volkow N.D., Gur R.C., Wang G.J., Fowler J.S., Moberg P.J., Ding Y.S., Hitzemann R., Smith G., and Logan J. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am. J. Psychiatry 155 (1998) 344-349
45. Wahl L., Chirakal R., Firnau G., Garnett E.S., and Nahmias C. The distribution and kinetics of [18F]6-fluoro-3-O-methyl-l-dopa in the human brain. J. Cereb. Blood Flow Metab. 14 (1994) 664-670
46. Woods R.P., Cherry S.R., and Maziotta J.C. Rapid automated algorithm for aligning and reslicing PET images. J. Comput. Assist. Tomogr. 16 (1992) 620-633